Prometic and Aventis Behring sign a development and collaboration agreement
06-Nov-2000
- Aventis Behring L.L.C. and ProMetic Life Sciences Inc.
(ProMetic; Toronto TSE symbol PLI), announced today that
they have signed a development and collaboration agreement
that provides Aventis Behring access to ProMetic's unique
purification/order_t/'>protein purification technology. Aventis Behring will fund the
development of a Mimetic LigandTM to isolate a specific
high-value therapeutic protein from plasma. The Mimetic
LigandTM will be generated from ProMetic's Intelligent
Combinatorial Libraries and will be designed to enhance
Aventis Behring's already rigorous therapeutic protein
purification procedures.
"Aventis Behring is pleased to partner with ProMetic as they
have an impressive track record for developing synthetic
ligands with high capacity and selectivity for therapeutic
proteins. We trust in ProMetic's ability to augment our
manufacturing processes while meeting our stringent quality
assurance requirements," said Dr. Fred Feldman, Vice
President and Chief Scientist, Research and Development,
Aventis Behring. "This agreement exemplifies Aventis
Behring's continued commitment to innovating and supplying
the highest quality therapeutic proteins for our patients
around the world."
"We are particularly pleased that Aventis Behring, a global
market leader in therapeutic proteins and recombinant
products, has chosen ProMetic's advanced technology to
further enhance its manufacturing process," commented
Pierre Laurin, President and Chief Executive Officer of
ProMetic. "This agreement further consolidates ProMetic's
position in the plasma and recombinant protein purification
market." Subject to regulatory approval, ProMetic anticipates
that its annual revenues from currently active worldwide
plasma-derived protein purification projects will exceed $50
million.
ProMetic owns proprietary enabling technology essential for
use in large-scale drug purification, chemical genomics,
proteomics, drug discovery and drug development. This
technology can significantly reduce costs, increase yield and
improve purity of existing and new bio-pharmaceutical
products. ProMetic accomplishes this through strategic
partnerships and in-house therapeutic development. The
headquarters of ProMetic Life Sciences Inc. are in Montreal
and it has operations in Canada, The United States and the
UK. Its shares are traded on the Toronto Stock Exchange
under the ticker symbol PLI. Additional information is
available on the company's website: www.prometic.com.
Aventis Behring L.L.C. is a global leader i